Exagen (XGN) Operating Income (2018 - 2026)

Exagen (XGN) has 9 years of Operating Income data on file, last reported at -$3.4 million in Q1 2026.

• Quarterly Operating Income fell 1.46% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 0.86% YoY) and the FY2025 annual result came in at -$14.1 million, down 3.18% from the prior year.
• Operating Income rose to -$3.4 million in Q1 2026, from -$5.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2.6 million in Q2 2024 to a low of -$14.5 million in Q4 2022.
• A 5-year average of -$5.9 million and a median of -$4.9 million in 2023 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2022 — Operating Income sank 144.93% — and 2023, when it soared 65.05%.
• Tracing XGN's Operating Income over 5 years: stood at -$14.5 million in 2022, then soared by 64.48% to -$5.1 million in 2023, then jumped by 34.27% to -$3.4 million in 2024, then tumbled by 47.06% to -$5.0 million in 2025, then jumped by 31.38% to -$3.4 million in 2026.
• The last three Operating Income figures came in at -$3.4 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.